|
業務類別
|
Biotechnology |
|
業務概覽
|
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. |
| 公司地址
| 3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219 |
| 電話號碼
| +1 972 499-3350 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.instilbio.com |
| 員工數量
| 14 |
| Mr. Bronson Crouch |
Chief Executive Officer and Chairman of the Board |
美元 712.04K |
14/04/2025 |
| Dr. Sandeep Laumas, M.D. |
Principal Accounting Officer, Chief Financial Officer and Chief Business Officer |
美元 508.60K |
14/04/2025 |
|
|
| Dr. Gwendolyn K. Binder, M.D. |
Independent Director |
14/04/2025 |
| Mr. George Matcham, PhD |
Independent Director |
14/04/2025 |
| Mr. Bronson Crouch |
Chief Executive Officer and Chairman of the Board |
14/04/2025 |
| Mr. R. Kent McGaughy, Jr |
Independent Director |
14/04/2025 |
| Dr. Neil Gibson,PhD |
Lead Independent Director |
14/04/2025 |
|
|
|
|
